Panobinostat (LBH589)
by Jessica Langholtz
Updated: Dec 3, 2009
Updated: Dec 3, 2009
| Brand Name: | |
| Generic Name: | panobinostat |
| Code Name: | LBH589 |
| Company: | Novartis |
| FDA Clinical Phase: | 1, 2, & 3 |
Description:
Panobinostat (news articles), which is a potent histone deacetylase (HDAC) inhibitor, selectively targets tumor cells for cell death. In Phase 1 trials, panobinostat was highly active as a single agent treatment for several types of cancer, including multiple myeloma, Hodgkin’s lymphoma, acute myeloid leukemia, and prostate cancer. Additional clinical trials are currently underway to examine the efficacy and safety profile of panobinostat.
Clinical Trials:
For a list of clinical trials studying panobinostat for the treatment of multiple myeloma, see ClinicalTrials.gov.
Official Web site for panobinostat: http://www.novartisoncology.com/research-innovation/pipeline/panobinostat.jsp
Related Articles:
- U.S. FDA Okays First Clinical Trial Of An Allogeneic CAR T-Cell Therapy For Multiple Myeloma
- Getting To Know: TNB-383B
- Number And Type Of Stem Cell Transplants Carried Out Each Year For Multiple Myeloma Vary Markedly Across U.S. Cancer Centers
- Dr. Craig Hofmeister On Testosterone And Multiple Myeloma
- bb2121 Continues To Impress As Potential New Multiple Myeloma Therapy (ASCO 2018)